These findings demonstrated that combined Src and EGFR inhibition decreases p-STAT3 activity, which increases the microvascular density within PDAC tumors, which ultimately results in increased delivery of cytotoxic chemotherapy into the tumor mass. Here, SRC is linked to neoplasm.